There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vera Therapeutics (VERA – Research Report) and MAIA Biotechnology, Inc. (MAIA – Research Report) with bullish sentiments.
Vera Therapeutics (VERA)
In a report released yesterday, Anupam Rama from J.P. Morgan maintained a Buy rating on Vera Therapeutics, with a price target of $22.00. The company’s shares closed last Tuesday at $6.14, close to its 52-week low of $5.20.
According to TipRanks.com, Rama is a 2-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Vera Therapeutics with a $14.25 average price target, which is a 129.8% upside from current levels. In a report issued on March 28, LifeSci Capital also maintained a Buy rating on the stock with a $18.00 price target.
See the top stocks recommended by analysts >>
MAIA Biotechnology, Inc. (MAIA)
In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on MAIA Biotechnology, Inc., with a price target of $14.00. The company’s shares closed last Tuesday at $3.84, close to its 52-week low of $3.06.
According to TipRanks.com, LeBoyer is a 1-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for MAIA Biotechnology, Inc. with a $14.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on VERA:
- Vera Therapeutics price target lowered to $11 from $15 at H.C. Wainwright
- Vera Therapeutics sees balance sheet funding operations to early 2026
- Vera Therapeutics announces upcoming milestones
- Vera Therapeutics reports 2022 EPS ($3.35), consensus ($3.12)
- Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
